Focusing on unmet needs in viral treatment
INAGEN develop novel biopharmaceuticals for better anti-viral treatment opportunities.
The company’s primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for novel treatment opportunities to treat CMV disease.
CMV infection affects more than half over all >100.000 transplant recipients world wide annually, causing transplant rejection, serious illness and even death if untreated. INAGEN will not only control the disease but strives to develop drugs that can eliminate the infection.
The company was founded by Dr. Thomas Kledal and CAT Science Park in 2007. INAGEN’s technology is based on 10 years of research from leading international institutions. The company’s laboratories are based in Lyngby approx. 12 kilometres outside Copenhagen